Surrozen (NASDAQ:SRZN – Get Free Report) and Swedish Orphan Biovitrum (OTCMKTS:BIOVF – Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.
Profitability
This table compares Surrozen and Swedish Orphan Biovitrum’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Surrozen | -2,885.33% | N/A | -112.96% |
| Swedish Orphan Biovitrum | 20.67% | 17.92% | 9.30% |
Analyst Recommendations
This is a summary of recent ratings and target prices for Surrozen and Swedish Orphan Biovitrum, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Surrozen | 1 | 1 | 5 | 0 | 2.57 |
| Swedish Orphan Biovitrum | 0 | 3 | 5 | 0 | 2.62 |
Surrozen presently has a consensus target price of $61.75, suggesting a potential upside of 95.35%. Given Surrozen’s higher probable upside, analysts plainly believe Surrozen is more favorable than Swedish Orphan Biovitrum.
Valuation & Earnings
This table compares Surrozen and Swedish Orphan Biovitrum”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Surrozen | $10.53 million | 34.86 | -$242.03 million | ($43.21) | -0.73 |
| Swedish Orphan Biovitrum | $2.89 billion | 6.30 | $48.85 million | $2.01 | 25.40 |
Swedish Orphan Biovitrum has higher revenue and earnings than Surrozen. Surrozen is trading at a lower price-to-earnings ratio than Swedish Orphan Biovitrum, indicating that it is currently the more affordable of the two stocks.
Volatility and Risk
Surrozen has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Swedish Orphan Biovitrum has a beta of 0.48, suggesting that its share price is 52% less volatile than the S&P 500.
Institutional and Insider Ownership
66.6% of Surrozen shares are owned by institutional investors. 31.7% of Surrozen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Swedish Orphan Biovitrum beats Surrozen on 8 of the 13 factors compared between the two stocks.
About Surrozen
Surrozen, Inc. is a biotechnology company developing antibody-based medicines designed to activate the Wnt signaling pathway, which plays a role in tissue growth and repair. The company uses its proprietary platform to develop therapies intended to stimulate regeneration in specific tissues while limiting effects elsewhere in the body. Surrozen’s research has included candidates aimed at liver disease and inflammatory bowel disease, including SZN-043 and SZN-1326. Its work focuses on advancing potential treatments through research and clinical development; the company’s products are investigational and are not approved medicines.
About Swedish Orphan Biovitrum
Swedish Orphan Biovitrum AB, known as Sobi, is a Swedish biopharmaceutical company focused on developing and providing treatments for rare and other serious diseases. Its work centers on hematology, immunology and specialized medicines for conditions with limited treatment options. Sobi’s portfolio includes therapies for blood disorders such as hemophilia, as well as treatments for rare inflammatory and immune-related conditions. The company also develops and commercializes medicines for other rare diseases, working with research and commercial partners where appropriate.
Receive News & Ratings for Surrozen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surrozen and related companies with MarketBeat.com's FREE daily email newsletter.
